Siemens Healthineers at AACC 2019

Industry-sponsored Workshops

Pre-registration is not required for the following sponsored workshops. Workshops are open to all congress attendees on a first-come, first-served basis.

Improving Outcomes with Effective Chronic-disease Management at the Point of Care
Tuesday, August 6 | 10:15—11:15 a.m. | Exhibit Hall | Theater 1

Download calendar blocker 7.5 kB

Summary

With increases in quality standards and patient volume, and continuing reduction of resources, this panel includes lively discussions of challenges and best practices in hospital chronic-disease patient management via point-of-care solutions.

Learning Objectives

• Identify current challenges in chronic-disease patient management for hospital systems.
• Map the value of point-of-care solutions to address chronic-disease patient management and increase staff efficiency.
• Understand how POC connectivity enables data collection and compliance.

Chair/moderator: Connie Mardis, Siemens Healthineers

Speakers
Joe Paul Gallo, RN, WHNP BC-E, MSN Ed, CST
Director of Chronic Disease Management and Communicable Disease, Denton County Public Health, TX, USA

Ann Hinson, MT(ASCP), CLS(NCA), Point of Care Specialist (AACC Certificate Program)
Director of Laboratory Services, Hudson River Community Health, Peekskill, NY, USA

Felicity Dempsey
Founder and Head of POCT Consultancy Services, Dublin, Ireland

Implementation of High-sensitivity Troponin I Starts in the Laboratory
Tuesday, August 6 | 12:45—1:45 p.m. | Exhibit Hall | Theater 1

Download calendar blocker 7.2 kB

Summary

High-sensitivity cardiac troponin assays can play a critical role in the expedited diagnosis of acute myocardial infarction. Successful implementation of high-sensitivity troponin I starts in the laboratory. Learn about the keys to a successful transition, along with the latest HIGH-US clinical trial data documenting the performance of the Atellica® IM High-Sensitivity Troponin I (TnIH) Assay.

Learning Objectives

• Understand the importance of high-sensitivity troponin I.
• Learn how to successfully implement high-sensitivity troponin I in your institution.
• Learn about the robust HIGH-US clinical trial data that demonstrates the performance of the Atellica IM TnIH Assay.

Chair/moderator: Melanie Pollan, Siemens Healthineers

Speakers
Alan Wu, PhD, DABCC, FACB
Chief, Clinical Chemistry and Toxicology Laboratories
Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA, USA

Robert H. Christenson, PhD, DABCC, FACB
Professor, Department of Pathology
University of Maryland, School of Medicine, Baltimore, MD, USA

Managing Patient Pathways and Improving Outcomes in NAFLD and NASH*
Tuesday, August 6 | 1:45—2:45 p.m. | Exhibit Hall | Theater 1

Download calendar blocker 8.8 kB

Summary

Nonalcoholic fatty liver disease (NAFLD), in which fat deposits in the liver, affects over 1 billion people globally¹ and is projected to become the leading cause of liver-related mortality within 20 years. ²Learn about current testing options that address this unmet clinical need.

Learning Objectives

• Understand the epidemiology of NAFLD and nonalcoholic steatohepatitis (NASH).
• Review practice guidelines and challenges in disease management.
• Learn about therapies and how noninvasive blood tests can help manage the NAFLD pathway.

Chair/moderator: Andrew Beard, Siemens Clinical Laboratory

Speakers
Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF
Chairman, Department of Medicine, Inova Fairfax Medical Campus
Professor of Medicine, Virginia Commonwealth University, Inova Campus
Affiliate Professor of Biomedical Sciences at George Mason University, Fairfax, VA, USA

Arun J. Sanyal, MD
Professor, Department of Internal Medicine
Division of Gastroenterology, Hepatology and Nutrition
Virginia Commonwealth University, Richmond, VA, USA

_{1Munteanu MA, Nagy GA, Mircea PA. Current management of NAFLD. Clujul Med. 2016;89(1):19-23. doi:10.15386/cjmed-539
2Ray K. NAFLD–the next global epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:621. doi: 10.1038/nrgastro.2013.197
*Presented by Siemens Clinical Laboratory}

Free Light Chain Testing in Diagnosis and Monitoring of Multiple Myeloma by N Latex FLC kappa and lambda Assays
Wednesday, August 7 | 3:30—4:30 p.m. | Exhibit Hall | Theater 1

Download calendar blocker 6.7 kB

Summary

Free light chain (FLC) kappa and lambda testing was incorporated in the diagnostic criteria for multiple myeloma requiring therapy by the International Myeloma Working Group in 2014. The test is also used to monitor response and relapse in light chain multiple myeloma (LCMM) and is frequently applied as an additional marker in multiple myeloma (MM) monitoring, together with serum and urine electrophoresis, immunofixation, and quantification of the M-protein. Data collected in a multicentric study comparing the N Latex FLC kappa and lambda method versus the FREELITE kappa and lambda method for diagnosis and monitoring of multiple myeloma patients and a comparison of both FLC methods versus clinical status will be presented.

Learning Objectives

• Describe the FLC kappa and lambda testing application for diagnosis and monitoring of multiple myeloma.
• Appraise the performance of N Latex FLC kappa and lambda assays compared to competitor methods.
• Review the clinical performance of N Latex FLC kappa and lambda assays for diagnosis and monitoring of multiple myeloma.

Chair/moderator: Dr. Claus Prümper, Siemens Healthineers

Speaker
Maria Alice V. Willrich, PhD
Assistant Professor of Laboratory Medicine and Pathology - Mayo Clinic College of Medicine and Science
Consultant - Division of Clinical Biochemistry & Immunology,
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA